 To assess the pharmacokinetics PK of ABX-EGF in combination with the FOLFIRI regimen in subjects with metastatic colorectal cancer. Secondary objectives in the original protocol were to assess the PK of ABX-EGF in combination with the Saltz regimen, and the PK of irinotecan IR and its active metabolite SN-38 when IR is given in combination with ABX-EGF, leucovorin LV, and 5-fluorouracil 5-FU in subjects with metastatic colorectal cancer 